Sie sind hier: Startseite > News > AUSTRALIAN HEALTH CARE COMPANY PRIMA

NEWS.

 

AUSTRALIAN HEALTH CARE COMPANY PRIMA

PRESS RELEASE Leipzig, May 28, 2010

AUSTRALIAN HEALTH CARE COMPANY PRIMA

The agreement represents a crucial step in the development and production of CVac™ in Europe. Establishment of a subsidiary in Leipzig is envisioned.

The preparation for production of CVac™ for the European trial has
already commenced, and Prima BioMed Ltd and the Fraunhofer IZI are
working together to prepare the facility to support CVac™ clinical trials
in Europe in early 2011. This represents a significant milestone on the
pathway to commercialisation of CVac™ in the European market.

In addition the agreement with Fraunhofer provides a number of other
key benefits to Prima BioMed Ltd. Fraunhofer is among the foremost
R&D institutes in Europe and it has strong collaborative networks
throughout academia, government, and industry. Fraunhofer will help
enhance the visibility of the CVac™ clinical program in Europe and
globally.

Prima Chief Operating Officer and Managing Director for Europe, Matthew Lehman said: “The Fraunhofer Institute is among the foremost
research and development organisations in the world and Prima is
delighted to enter into this collaborative arrangement (…)”. Fraunhofer
IZI Head of Cell Therapy Production, Dr. Gerno Schmiedeknecht, commented: “Cell therapies are a cutting-edge technology with the potential to significantly benefit patients. The Fraunhofer IZI is at the forefront of this technology in Europe and we are very excited to help develop Prima’s CVac™.”

The Fraunhofer-Gesellschaft undertakes applied research of direct utility to private and public enterprise and of wide benefit to society.

The Fraunhofer Institute for Cell Therapy and Immunology IZI is member of the Fraunhofer Group for Life Sciences. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated
in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.

Contact:
Fraunhofer-Institut für Zelltherapie
und Immunologie

Dr. Wilhelm Gerdes
Phone +49 (0) 341/355 36-9300
Fax +49 (0) 341/355 36-9912
wilhelm.gerdes@izi.fraunhofer.de

Perlickstraße 1
04103 Leipzig

info@izi.fraunhofer.de
www.izi.fraunhofer.de

PRESS RELEASE Leipzig, May 28, 2010 (pdf)
 

Artikelaktionen